(111)Indium Labelling of Recombinant Activated Coagulation Factor VII: In Vitro and Preliminary In Vivo Studies in Healthy Rats
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
(111)Indium Labelling of Recombinant Activated Coagulation Factor VII : In Vitro and Preliminary In Vivo Studies in Healthy Rats. / Nalla, Amarnadh; Buch, Inge; Sigvardt, Maibritt; Bodholdt, Rasmus Poul; Kjaer, Andreas; Hesse, Birger.
In: International Journal of Molecular Imaging, Vol. 2012, 2012.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - (111)Indium Labelling of Recombinant Activated Coagulation Factor VII
T2 - In Vitro and Preliminary In Vivo Studies in Healthy Rats
AU - Nalla, Amarnadh
AU - Buch, Inge
AU - Sigvardt, Maibritt
AU - Bodholdt, Rasmus Poul
AU - Kjaer, Andreas
AU - Hesse, Birger
PY - 2012
Y1 - 2012
N2 - The aim of this study is to investigate whether (111)Indium-labelled recombinant FVIIa (rFVIIa) could be a potential radiopharmaceutical for localization of bleeding sources. DTPA-conjugated rFVIIa was radiolabelled with (111)In chloride. In vitro binding efficiency of (111)In-DTPA-rFVIIa to F1A2-Mab-sepharose was 99% in buffer, while it was 88-82% in serum. The binding efficiency of (111)In-DTPA-rFVIIa to TF (1-209)-sepharose was 48% in buffer whereas 39%-36% in serum, respectively. In vivo experiment was conducted in healthy rats, and gamma camera images were taken immediately after iv. administration of 1.6-1.8 MBq (111)In-DTPA-rFVIIa up to 120-130 min. Five min after administration of (111)In-DTPA-rFVIIa, percentage of (111)In activity was 6.0% in the cardiac region and 24.5% in the liver region. After 2 hours activity was decreased to 3.3% in heart while it had increased to 42.0% in the liver. The (111)In-DTPA-rFVIIa might be a potential radiopharmaceutical for visualisation of tissues with significant TF expression such as acute bleeding lesions in the gastrointestinal tract.
AB - The aim of this study is to investigate whether (111)Indium-labelled recombinant FVIIa (rFVIIa) could be a potential radiopharmaceutical for localization of bleeding sources. DTPA-conjugated rFVIIa was radiolabelled with (111)In chloride. In vitro binding efficiency of (111)In-DTPA-rFVIIa to F1A2-Mab-sepharose was 99% in buffer, while it was 88-82% in serum. The binding efficiency of (111)In-DTPA-rFVIIa to TF (1-209)-sepharose was 48% in buffer whereas 39%-36% in serum, respectively. In vivo experiment was conducted in healthy rats, and gamma camera images were taken immediately after iv. administration of 1.6-1.8 MBq (111)In-DTPA-rFVIIa up to 120-130 min. Five min after administration of (111)In-DTPA-rFVIIa, percentage of (111)In activity was 6.0% in the cardiac region and 24.5% in the liver region. After 2 hours activity was decreased to 3.3% in heart while it had increased to 42.0% in the liver. The (111)In-DTPA-rFVIIa might be a potential radiopharmaceutical for visualisation of tissues with significant TF expression such as acute bleeding lesions in the gastrointestinal tract.
U2 - 10.1155/2012/464810
DO - 10.1155/2012/464810
M3 - Journal article
C2 - 22518302
VL - 2012
JO - International Journal of Molecular Imaging
JF - International Journal of Molecular Imaging
SN - 2090-1712
ER -
ID: 41800604